

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 2023 I

#7

David Fox Fullbright & Jaworski 1301 McKinney, Suite 5100 Houston, Texas 77010-3095

In re Application of BACHYNSKY et al.

U.S. Application No. 09/744,622

PCT No.: PCT/US99/16940

Int. Filing Date: 27 July 1999

Priority Date: 27 July 1998

Attorney Docket No.: HO-P01615WO0

For: CHEMICALLY INDUCED

INTRACELLULAR HYPERTHERMIA

DECISION ON PETITION UNDER 37 CFR 1.47(b)

This is a decision on applicants' "Renewed Petition under 37 C.F.R. 1.47(b)" filed 07 May 2002 to accept the application without the signature of the inventors, Nicholas Bachynsky and Woodie Roy. No petition fee is due.

## **BACKGROUND**

On 27 July 1999, applicants filed international application no. PCT/US99/16940 which claimed a priority date of 27 July 1998. A proper Demand was filed with the International Preliminary Examining Authority prior to the 19th month from the earliest claimed priority date. Accordingly, the thirty-month time period for submitting the requisite basic national fee in the United States of America was extended to expire 30 months from the priority date, i.e., 29 January 2001.


On 26 January 2001, applicants filed a transmittal letter for entry into the national stage in the United States, which was accompanied by the requisite basic national fee as required by 35 U.S.C. 371(c)(1) and a copy of the international application.

On 12 March 2001, the United Stated Designated/Elected Office mailed a Notification of Missing Requirements under 35 U.S.C. 371 (Form PCT/DO/EO/905) indicating that an oath or declaration in compliance with 37 CFR 1.497 must be filed. The notification set a one-month time limit in which to respond.

On 05 September 2001, applicants filed "Petition under 37 C.F.R. 1.47(b)" and a three-month extension. The petition was dismissed in a Decision dated 08 November 2001.

On 07 May 2002, applicants filed the present petition and a four-month extension of time.







## DISCUSSION

A petition under 37 CFR 1.47(b) must be accompanied by: (1) the requisite petition fee under 37 CFR 1.17(i); (2) factual proof that the inventor refuses to execute the application or cannot be reached after diligent effort; (3) a statement of the last known address of the nonsigning inventor; (4) an oath or declaration executed by the 37 CFR 1.47(b) applicant on behalf of and as agent for the nonsigning inventor; (5) proof of proprietary interest in the application; and (6) a showing that such action is necessary to preserve the rights of the parties or to prevent irreparable damages. The 37 CFR 1.47(b) applicant has satisfied the requirements of items (1),(3), and (6). However, items (2) and(5) have not been satisfied.

Regarding Item (2), section 409.03(d) of the Manual of Patent Examining Procedure (M.P.E.P.), **Proof of Unavailability or Refusal**, states, in part:


A copy of the application papers should be sent to the last known address of the nonsigning inventor, or, if the nonsigning inventor is represented by counsel, to the address of the nonsigning inventor's attorney.

Where a refusal of the inventor to sign the application papers is alleged, the circumstances of the presentation of the application papers and of the refusal must be specified in a statement of facts by the person who presented the inventor with the application papers and/or to whom the refusal was made. Statements by a party not present when an oral refusal is made will not be accepted.

Proof that a bona fide attempt was made to present a copy of the application papers (specification, including claims, drawings, and oath or declaration) to the nonsigning inventor for signature, but the inventor refused to accept delivery of the papers or expressly stated that the application papers should not be sent, may be sufficient. When there is an express oral refusal, that fact along with the time and place of the refusal must be stated in the statement of facts. When there is an express written refusal, a copy of the document evidencing that refusal must be made part of the statement of facts. The document may be redacted to remove material not related to the inventor's reasons for refusal.

When it is concluded by the 37 CFR 1.47 applicant that a nonsigning inventor's conduct constitutes a refusal, all facts upon which that conclusion is based should be stated in the statement of facts in support of the petition or directly in the petition. If there is documentary evidence to support facts alleged in the petition or in any statement of facts, such evidence should be submitted.

Whenever a nonsigning inventor gives a reason for refusing to sign the application oath or declaration, that reason should be stated in the petition.





As to Item (2), a review of the present petition and accompanying papers reveal that applicant has shown that a bona fide attempt was made to present the application papers, including specification, claims, and drawings to Nicholas Bachynsky and Woodie Roy. Additionally, the declaration of G. Wayne Choate states that "the inventors refuse to sign the declarations." However, it is unclear whether the declarant is inferring this conclusion on the actions of the missing inventor; or if Mr. Choate is basing this conclusion on conversations he has had with missing inventors or their counsel. If declarant is relying upon an oral refusal, the declaration must provide sufficient detail of the reasons surrounding the refusal and if that refusal is intended to be relied upon. As stated above, whenever a nonsigning inventor gives a reason for refusing to sign the application oath or declaration, that reason should be stated in the petition.

Concerning Item (5), section 409.03(f) of the M.P.E.P., **Proof of Proprietary Interest**, states, in part:


When an application is deposited pursuant to 37 CFR 1.47(b), the 37 CFR 1.47(b) applicant must prove that (A) the invention has been assigned to the applicant, or (B) the inventor has agreed in writing to assign the invention to the applicant, or (C) the applicant otherwise has sufficient proprietary interest in the subject matter to justify the filing of the application.

If the application has been assigned, a copy of the assignment (in the English language) must be submitted. The assignment must clearly indicate that the invention described in the 37 CFR 1.47(b) application was assigned to the 37 CFR 1.47(b) applicant. A statement under 37 CFR 3.73(b) by the assignee must also be submitted (see MPEP § 324). An assignment of an application and any "reissue, division, or continuation of said application" does not itself establish an assignment of a continuation-in-part application. In re Gray, 115 USPQ 80 (Comm'r Pat. 1956). An assignment to a 37 CFR 1.47(b) applicant for the sole purpose of obtaining a filing date for a 37 CFR 1.47(b) application is not considered an assignment within the meaning of 35 U.S.C. 118 and 37 CFR 1.47(b).

When an inventor has agreed in writing to assign an invention described in an application deposited pursuant to 37 CFR 1.47(b), a copy of that agreement should be submitted. If an agreement to assign is dependent on certain specified conditions being met, it must be established by a statement of facts by someone with first hand knowledge of the circumstances in which those conditions have been met. A typical agreement to assign is an employment agreement where an employee (nonsigning inventor) agrees to assign to his or her employer (37 CFR 1.47(b) applicant) all inventions made during employment. When such an agreement is relied on, it must be established by a statement of a person having

firsthand knowledge of the facts that the invention was made by the employee while employed by the 37 CFR 1.47(b) applicant.





If the invention has not been assigned, or if there is no written agreement to assign, the 37 CFR 1.47(b) applicant must demonstrate that he or she otherwise has a sufficient proprietary interest in the matter.

A proprietary interest obtained other than by assignment or agreement to assign may be demonstrated by an appropriate legal memorandum to the effect that a court of competent jurisdiction (federal, state, or foreign) would by the weight of authority in that jurisdiction award title of the invention to the 37 CFR 1.47(b) applicant. The facts in support of any conclusion that a court would award title to the 37 CFR 1.47(b) applicant should be made of record by way of an affidavit or declaration of the person having firsthand knowledge of same. The legal memorandum should be prepared and signed by an attorney at law familiar with the law of the jurisdiction involved. A copy (in the English language) of a statute (if other than the United States statute) or a court decision (if other than a reported decision of a federal court or a decision reported in the United States Patents Quarterly) relied on to demonstrate a proprietary interest should be made of record.

Regarding Item (5), petitioner has not demonstrated that applicant has a proprietary interest in the invention. Petitioner has provided an Assignment executed by Nicholas Bachynsky and Woodie Roy. As stated in the previous petition; the assignments of the "invention" to Texas Pharmaceutical, Inc., show sufficient proprietary interest, however, these assignments are not acceptable to establish ownership and file the application under 37 CFR 1.47(b). The assignments do not identify the instant application by application number.

For the reasons stated above, it would not be appropriate to accept the application without the signature of Nicholas Bachynsky and Woodie Roy under 37 CFR 1.47(b) at this time.

## **CONCLUSION**

The renewed petition filed under 37 CFR 1.47(b) is **DISMISSED** without prejudice.

If reconsideration on the merits of this petition is desired, a proper response must be filed within <u>TWO MONTHS</u> from the mailing date of this decision. Any reconsideration request should include a cover letter entitled "Renewed Petition Under 37 CFR 1.47(b).





Application No.:09/744,622

Please direct any further correspondence with respect to this matter to the Assistant Commissioner for Patents, Box PCT, Washington, D.C. 20231, and address the contents of the letter to the attention of the Legal Affairs Division of the PCT Legal Office.

Leonard Smith

PCT Legal Examiner

Office of PCT Legal Administration

Anthony Smith

Attorney-Advisor

Office of PCT Legal Administration

Telephone 703-308-6314

Fax: 703-308-6459